Taspoglutide
- Generic Name
- Taspoglutide
- Drug Type
- Small Molecule
- Chemical Formula
- C152H232N40O45
- CAS Number
- 275371-94-3
- Unique Ingredient Identifier
- 2PHK27IP3B
- Background
Taspoglutide is a pharmaceutical drug, a glucagon-like peptide-1 agonist (GLP-1 agonist), under investigation for treatment of type 2 diabetes being codeveloped by Ipsen and Roche. In September 2010 Roche halted Phase III clinical trials due to incidences of serious hypersensitivity reactions and gastrointestinal side effects. As of May 2013 no new trials had been registered.
FDA Approves Rival Diabetes Combinations Xultophy and Soliqua for Type 2 Diabetes Management
• The FDA has simultaneously approved two novel diabetes combination therapies: Novo Nordisk's Xultophy (insulin degludec/liraglutide) and Sanofi's Soliqua (insulin glargine/lixisenatide) for type 2 diabetes management.
• Clinical trials demonstrated Xultophy's superior efficacy, with patients 4.5 times more likely to achieve glycemic targets without hypoglycemia compared to Lantus alone.
• Both once-daily injectable combinations will enter the US market in early 2017, with Soliqua launching in January and Xultophy following in the first half of the year.
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.
© Copyright 2025. All Rights Reserved by MedPath